Hypertension and Polycystic Ovary Syndrome Among Women in a Nationwide Electronic Health Records Dataset in the United States
- PMID: 40889056
- DOI: 10.1007/s10995-025-04155-x
Hypertension and Polycystic Ovary Syndrome Among Women in a Nationwide Electronic Health Records Dataset in the United States
Abstract
Introduction: Both hypertension and polycystic ovary syndrome (PCOS) are risk factors for future cardiovascular diseases among women of reproductive age (18-44 years). We constructed an electronic health record (EHR)-based PCOS phenotype, reported PCOS prevalence, and investigated the association of PCOS and hypertension in the United States (US).
Methods: This cross-sectional study used 2022 IQVIA's Ambulatory Electronic Medical Record (AEMR)-US data (May 2023 release). We constructed a phenotype for PCOS and reported PCOS prevalence for eligible women. We then described hypertension prevalence and hypertension control estimates stratified by PCOS status. Lastly, we calculated adjusted prevalence ratios (aPR) for hypertension and hypertension control by PCOS status, adjusting for age, race, and body mass index (BMI).
Results: We analyzed records for 1,301,425 eligible women, with mean (standard deviation) age of 31.5 (7.9) years. The prevalence of PCOS was 2.1%, but increased with weight category, reaching 6.7% among those with class 3 obesity (BMI ≥ 40 kg/m2). Women with PCOS had 50% higher prevalence of hypertension than those without PCOS (aPR 1.50; 95% confidence interval [CI]: 1.48-1.52; p < 0.001), and slightly higher hypertension control prevalence (aPR 1.14; 95% CI: 1.12-1.17; p < 0.001).
Discussion: Using a nationwide EHR dataset, we observed that women with PCOS had substantially higher hypertension prevalence than those without PCOS. PCOS prevalence was lower than previous estimates from global surveys. Following guideline-recommended blood pressure screening for women with PCOS could reduce the risk of long-term cardiovascular disease.
Keywords: Cardiovascular disease; Electronic health records; Hypertension; Polycystic ovary syndrome; Women’s health.
© 2025. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
Declarations. Conflict of interest: The authors have no conflict of interest to declare. Ethical Approval: The Centers for Disease Control and Prevention (CDC) reviewed this activity, conducted consistent with applicable federal law and CDC policy: 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Section 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. Section 3501 et seq.
Similar articles
-
High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis.Hum Reprod. 2017 May 1;32(5):1075-1091. doi: 10.1093/humrep/dex044. Hum Reprod. 2017. PMID: 28333286
-
Ovarian surgery for symptom relief in women with polycystic ovary syndrome.Cochrane Database Syst Rev. 2017 Nov 10;11(11):CD009526. doi: 10.1002/14651858.CD009526.pub2. Cochrane Database Syst Rev. 2017. PMID: 29125183 Free PMC article.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Facial emotion recognition accuracy in women with symptoms of polycystic ovary syndrome: Reduced fear and disgust perception.Womens Health (Lond). 2025 Jan-Dec;21:17455057251359761. doi: 10.1177/17455057251359761. Epub 2025 Jul 28. Womens Health (Lond). 2025. PMID: 40726090 Free PMC article.
-
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6. Cochrane Database Syst Rev. 2017. PMID: 29183107 Free PMC article.
References
-
- Actkins, K. V., Singh, K., Hucks, D., Velez Edwards, D. R., Aldrich, M., Cha, J., Wellons, M., & Davis, L. K. (2021). Characterizing the clinical and genetic spectrum of polycystic ovary syndrome in electronic health records. The Journal of Clinical Endocrinology and Metabolism, 106(1), 153–167. https://doi.org/10.1210/clinem/dgaa675 - DOI - PubMed
-
- American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. (2018). ACOG practice bulletin 194: Polycystic ovary syndrome. Obstetrics and Gynecology, 131(6), e157–e171. https://doi.org/10.1097/AOG.0000000000002656 - DOI
-
- Amiri, M., Ramezani Tehrani, F., Behboudi-Gandevani, S., Bidhendi-Yarandi, R., & Carmina, E. (2020). Risk of hypertension in women with polycystic ovary syndrome: A systematic review, meta-analysis and meta-regression. Reproductive Biology and Endocrinology: RB&E, 18(1), 23. https://doi.org/10.1186/s12958-020-00576-1 - DOI
-
- Canoy, D., Nazarzadeh, M., Copland, E., Bidel, Z., Rao, S., Li, Y., & Rahimi, K. (2022). How much lowering of blood pressure is required to prevent cardiovascular disease in patients with and without previous cardiovascular disease? Current Cardiology Reports,24(7), 851–860. https://doi.org/10.1007/s11886-022-01706-4 - DOI - PubMed - PMC
-
- Christ, J. P., & Cedars, M. I. (2023). Current guidelines for diagnosing PCOS. Diagnostics. https://doi.org/10.3390/diagnostics13061113 - DOI - PubMed - PMC
LinkOut - more resources
Full Text Sources
Miscellaneous